Uta Lichter-Konecki

Uta Lichter-Konecki

Auto-generated profile, based on publicly available information

Uta Lichter-Konecki

Division of Genetic and Genomic Medicine, UPMC Children’s Hospital of Pittsburgh, University of Pittsburgh, Pittsburgh, USA

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 March 2019 in Drugs
Verified
Journal Article
Closed access
PDF file
ULUta Lichter-Konecki
Uta Lichter-Konecki
JVJerry Vockley
Jerry Vockley

15 October 2020 in JCI Insight
Verified
Journal Article
Open access
PDF file
EKErik A. Koppes
Erik A. Koppes
BRBethany K. Redel
Bethany K. Redel
MJMarie A. Johnson
Marie A. Johnson
KSKristen J. Skvorak
Kristen J. Skvorak
LGLina Ghaloul-Gonzalez
Lina Ghaloul-Gonzalez
RNRobert D. Nicholls
Robert D. Nicholls
Phenylalanine hydroxylase–deficient (PAH-deficient) phenylketonuria (PKU) results in systemic hyperphenylalaninemia, leading to neurotoxicity with severe developmental disabilities. Dietary phenylalanine (Phe) restriction prevents the most deleterious effects of hyperphenylalaninemia, but adherence to diet is poor in adult and adolescent patients, resulting in characteristic neurobehavioral phenotypes. Thus, an urgent need exists for new treatments. Additionally, rodent models of PKU do not adequately reflect neurocognitive phenotypes, and thus there is a need for improved animal models. To this end, we have developed PAH -null pigs. After selection of optimal CRISPR/Cas9 genome-editing reagents by using an in vitro cell model, zygote injection of 2 sgRNAs and Cas9 mRNA demonstrated deletions in preimplantation embryos, with embryo transfer to a surrogate leading to 2 founder animals. One pig was heterozygous for a PAH exon 6 deletion allele, while the other was compound heterozygous for deletions of exon 6 and of exons 6–7. The affected pig exhibited hyperphenylalaninemia (2000–5000 μM) that was treatable by dietary Phe restriction, consistent with classical PKU, along with juvenile growth retardation, hypopigmentation, ventriculomegaly, and decreased brain gray matter volume. In conclusion, we have established a large-animal preclinical model of PKU to investigate pathophysiology and to assess new therapeutic interventions.

Verified
Journal Article
Open access
PDF file
JPJessica R. C. Priestley
Jessica R. C. Priestley
LALaura A. Adang
Laura A. Adang
SWSarah Drewes Williams
Sarah Drewes Williams
ULUta Lichter-Konecki
Uta Lichter-Konecki
CMCaitlin Menello
Caitlin Menello
Can FiciciogluCan Ficicioglu
Can Ficicioglu
X-linked adrenoleukodystrophy (X-ALD) is the most common peroxisomal disorder. It results from pathogenic variants in ABCD1, which encodes the peroxisomal very-long-chain fatty acid transporter, causing a spectrum of neurodegenerative phenotypes. The childhood cerebral form of the disease is particularly devastating. Early diagnosis and intervention improve outcomes. Because newborn screening facilitates identification of at-risk individuals during their asymptomatic period, X-ALD was added to the Pennsylvania newborn screening program in 2017. We analyzed outcomes from the first four years of X-ALD newborn screening, which employed a two-tier approach and reflexive ABCD1 sequencing. There were 51 positive screens with elevated C26:0-lysophosphatidylcholine on second-tier screening. ABCD1 sequencing identified 21 hemizygous males and 24 heterozygous females, and clinical follow up identified four patients with peroxisomal biogenesis disorders. There were two false-positive cases and one false-negative case. Three unscreened individuals, two of whom were symptomatic, were diagnosed following their young siblings’ newborn screening results. Combined with experiences from six other states, this suggests a U.S. incidence of roughly 1 in 10,500, higher than had been previously reported. Many of these infants lack a known family history of X-ALD. Together, these data highlight both the achievements and challenges of newborn screening for X-ALD.

1 August 1991 in Human Genetics
Verified
Journal Article
Closed access
PDF file
DKD. S. Konecki
D. S. Konecki
MSM. Schlotter
M. Schlotter
FTFriedrich Trefz
Friedrich Trefz
ULU. Lichter-Konecki
U. Lichter-Konecki

1 April 2018 in Pediatric Clinics of North America
Verified
Journal Article
Closed access
ESEvgenia Sklirou
Evgenia Sklirou
ULUta Lichter-Konecki
Uta Lichter-Konecki

26 August 2016 in Translational Science of Rare Diseases
Verified
Journal Article
Open access
PDF file
ULUta Lichter-Konecki
Uta Lichter-Konecki
The elimination of waste nitrogen as urea is a final and central step of amino acid catabolism. It is accomplished by one of the most essential pathways of terrestrial animals, the urea cycle. This article describes the basic function of the 5 catalytic enzymes, the two transporters, and the cofactor synthesizing enzyme that comprise the urea cycle as well as the consequences of their deficiencies and ways to treat them. The article then elaborates on related disorders of metabolism that may either cause hyperammonemia or elevation of an amino acid that is key to urea cycle function.